Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 27, 2025 06:00 ET | Source: Amphista Therapeutics

Amphista Therapeutics’ successful degradation of a key cancer target, BRD9, via a novel mechanism with DCAF16 E3 ligase published in Nature Communications

The publication reports the highly selective, DCAF16 E3 enabled degradation of BRD9 in vivo using Amphista’s proprietary, next generation Targeted Glue™ medicinal chemistry technologyAmphista’s...
May 22, 2025 08:00 ET | Source: Amphista Therapeutics

Amphista Therapeutics showcases cryo-EM enabled platform for discovering novel Targeted Glue™ degraders at SLAS Europe 2025

Innovative Eclipsys® platform enables rational design of novel Targeted Glues™ with superior drug-like properties Cambridge, UK, 22 May 2025 – Amphista Therapeutics, a leader in the discovery of...